Evaluation Targeted Strategies in the Management of Non-Small Cell Lung Cancer: A Focus on EGFR Gene Mutations Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Catherine Shu, MD 5 4 3 2 1 Edward Garon, MD, MS 5 4 3 2 1 Corey Langer, MD, FACP 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe common EGFR gene mutations in NSCLC as well as current guidelines for the identification of these alterations 5 4 3 2 1 Evaluate the safety/efficacy data and sequencing strategies of available and emerging EGFR-targeted therapies 5 4 3 2 1 Implement strategies to mitigate, manage, and anticipate adverse events associated with EGFR-targeted therapies in order to improve patient outcomes and minimize NSCLC treatment interruption 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with NSCLC on a monthly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage NSCLC. Excellent Very Good Good Fair Poor Based on my participation in this activity, I anticipate I will more often: (select all that apply) Remain apprised of common EGFR gene mutations in NSCLC as well as current guidelines for the identification of these alterations Review current guidelines and recommendations for the optimal treatment of EGFR+ NSCLC Evaluate the safety and efficacy of current/emerging treatment options for patients with EGFR+ NSCLC Assess factors that influence therapeutic sequencing in EGFR+ NSCLC, including treatment resistance Implement strategies to mitigate, manage, and anticipate adverse events associated with EGFR-targeted therapies Implement patient/caregiver education into routine practice to improve NSCLC outcomes and care Implement multidisciplinary care strategies for the optimal management of NSCLC Other (please specify): Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max The majority of EGFR mutations in NSCLC occur in which of the following locations? Exons 14-17 Exons 16-19 Exons 18-21 Exons 20-23 In patients with advanced EGFR-mutant NSCLC, primary results from the Phase 3 MARIPOSA-2 study revealed which of the following? Amivantamab–erlotinib–chemotherapy improved OS and intracranial PFS versus chemotherapy Amivantamab–lazertinib–chemotherapy demonstrated improved PFS versus chemotherapy after disease progression on osimertinib Erlotinib–chemotherapy demonstrated improved PFS versus chemotherapy after disease progression on osimertinib Lazertinib–chemotherapy improved OS and intracranial PFS versus chemotherapy Prior to amivantamab treatment, which of the following premedication strategies is required to reduce the risk of infusion-related reactions? Intravenous acetaminophen (1,500 mg) or equivalent Intravenous dexamethasone (20mg) or equivalent Oral acetaminophen (1,500 mg) Oral dexamethasone (20mg) How confident are you now in your ability to mitigate, manage, and anticipate adverse events associated with EGFR-targeted therapies? Very confident Confident Somewhat confident Not very confident Not at all confident Previous
